The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
Bollywood veteran Farida Jalal couldn't resist a cheeky remark about producer Sajid Nadiadwala's impressive 27-inch waistline, fueling ongoing rumors that Ozempic fueled his dramatic body transformation. As his film O Romeo hits theaters, the chatter highlights growing celebrity interest in GLP-1 medications for weight loss. Explore the story and science behind it.
GLP-1 weight loss drugs such as Wegovy and Zepbound have revolutionized obesity care, leading to up to 20% body weight reduction over 72 weeks. These therapies challenge old views of obesity as mere lifestyle failure, highlighting brain hunger centers, genetics, and hormones. From chronic disease recognition to equitable access, here's how they've reshaped treatment.
Eli Lilly is sending a clear signal of confidence in its upcoming GLP-1 obesity pill, orforglipron, by stockpiling $1.5 billion worth of inventory ahead of FDA approval. This move, up from $550 million last year, anticipates robust demand without the supply chain issues that plagued injectables like Wegovy from 2022-2024. Here's what it means for patients seeking oral weight loss options.
Jelly Roll's wife, Bunnie Xo, described a 'horrific' bout of suicidal ideation as a side effect from taking a GLP-1 medication last year. The Dumb Blonde podcast host opened up to PEOPLE about this dark period, emphasizing the need for open conversations on GLP-1 side effects. Despite family diabetes history prompting her use, she urges others: 'Please stay.'
Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.
Popular GLP-1 drugs like Ozempic and Wegovy are curbing appetites, prompting restaurants to adapt with specialized menus. Cuba Libre's Barry Gutin explains their high-protein, smaller-portion offerings designed with a doctor's input. This trend signals a lasting change in dining habits.
GLP-1 medications like Ozempic and Wegovy have surged in popularity for weight loss and Type II diabetes management, but celebrities are now sharing alarming side effects. Bunnie Xo revealed suicidal ideations after using one, while her husband Jelly Roll shed nearly 300 pounds naturally. This guide examines the risks and promotes healthier paths.
McDonald's executives revealed plans to cater to the growing number of customers on GLP-1 drugs like Ozempic during their latest earnings call. With users seeking high-protein options and avoiding sugary drinks, the chain is testing menu tweaks. This shift reflects broader changes in the food industry as GLP-1 adoption hits 10% of the US population.
A nasal spray version of semaglutide, the active ingredient in Ozempic and Wegovy, could soon offer an affordable alternative for weight loss. Chinese firm Shanghai Shiling Pharmaceutical is advancing trials, aiming for global markets by 2028 amid soaring demand. This development aligns with Novo Nordisk's upcoming patent loss in China, paving the way for cheaper generics.
